Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
cyproterone acetate, Quantity: 100 mg
Strides Pharma Science Pty Ltd
cyproterone acetate
Tablet, uncoated
Excipient Ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate
Oral
50 tablets
(S4) Prescription Only Medicine
Inoperable prostatic carcinoma. To suppress flare with initial luteinising hormone releasing hormone (LHRH) analogue therapy; in long-term palliative treatment where LHRH analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with LHRH analogues or who have had orchidectomy.
Visual Identification: White to off white, capsule shaped tablet with '100' engraved on one face, and a break line on the other face.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 3 Years; Container Temperature: Store below 30 degrees Celsius
Registered
2012-05-23
CYROTONE-100™ CONSUMER MEDICINE INFORMATION Cyproterone acetate 100 mg tablets WHAT IS IN THIS LEAFLET This leaflet answers some of the common questions about CYROTONE-100 tablets. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking CYROTONE-100 tablets against the benefits the medicine is expected to have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. Keep this leaflet with the medicine. You may need to read it again. WHAT IS CYROTONE-100 USED FOR AND HOW DOES IT WORK CYROTONE-100 is an anti-androgenic hormone medication containing the active ingredient cyproterone acetate which is used to treat cancer of the prostate gland. Androgens such as testosterone are natural male sex hormones. In some types of prostate cancer, androgens may help the cancer cells to grow. By blocking these hormones CYROTONE-100 may slow or stop the growth of cancer. CYROTONE-100 may also be used in conjunction with other medications or following surgical removal of the testes to treat side effects such as hot flushes or sweats and to prevent any initial worsening of the disease. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another reason. CYROTONE-100 is only available on a doctor’s prescription. There is no evidence that CYROTONE-100 tablets are addictive. BEFORE YOU TAKE CYROTONE-100 _WHEN YOU MUST NOT TAKE IT _ DO NOT TAKE CYROTONE-100 IF YOU HAVE AN ALLERGY TO: • cyproterone acetate, the active ingredient in CYROTONE-100 • any of the ingredients listed at the end of this leaflet Some of the symptoms of an allergic reaction may include: • shortness of breath; • wheezing or difficulty breathing; • swelling of the face, lips, tongue or other parts of the body; or • rash, itching or hives on the skin. DO NOT TAKE CYROTONE-100 IF YOU HAVE Read the complete document
Page 1 of 8 PRODUCT INFORMATION CYROTONE-100 100 MG TABLETS NAME OF THE MEDICINE The active ingredient in CYROTONE-100 is: cyproterone acetate. Chemical structure: Molecular formula: C 24 H 29 ClO 4 Molecular mass: 416.96 CAS registry number: 427-51-0 Chemical name: 6-chloro-17 hydroxy-1 ,2 -methylene-pregna-4,6-diene-3,20-dione acetate. DESCRIPTION Cyproterone acetate is a white to almost white crystalline powder. It is practically soluble in water, very soluble in methylene chloride, freely soluble in acetone, soluble in methanol, sparingly soluble in anhydrous ethanol. Along with cyproterone acetate CYROTONE-100 also contains: microcrystalline cellulose, lactose, croscarmellose sodium, povidone and magnesium stearate. PHARMACOLOGY ATC code: G03HA01 Pharmacotherapeutic group: Antiandrogens, plain. Cyproterone acetate inhibits competitively the effect of androgens at androgen-dependent target organs, e.g. it shields the prostate from the effect of androgens originating from the gonads and/or the adrenal cortex. Prostatic carcinoma and its metastases are in general androgen-dependent, cyproterone acetate therefore exerts a direct antiandrogenic action on the tumour and its metastases. Page 2 of 8 Cyproterone acetate in addition has a progoestogenic action exerting a negative feedback effect centrally on the hypothalamic receptors, so leading to a reduction in gonadotropin release, and hence to diminished production of testicular androgens. Treatment with cyproterone acetate in men results in a reduction of sexual drive and potency and inhibition of gonadal function. These changes are reversible following discontinuation of the therapy. The function of androgen dependent target organs, such as the prostate, is restricted. The anti-gonadotropic effect of cyproterone acetate is also exerted when the substance is combined with LHRH agonists. The initial increase of testosterone provoked by this substance group is decreased by cyproterone acetate. Serum prolactin levels may increase with higher doses of CP Read the complete document